Implications of elevated levels of prostaglandin I2 and thromboxane A2 in type I hepatorenal syndrome

Gao BaoXiu; Nie Xin; Wu Bin; He Yong; Song HaoLan; Luo TongXing; Xu Jing; Li GuiXing

Issue 11

Nov. 2012

Turn off MathJax

Article Contents

References

Article Navigation > Journal of Clinical Hepatology > 2012 > 28(11): 860-862

PDF( 1115 KB)

Implications of elevated levels of prostaglandin I2 and thromboxane A2 in type I hepatorenal syndrome

Research funding:

Published Date: 2012-11-20

Abstract

FullText(HTML)

References(0)

References

Relative Articles

[1]	Rong SUN, Li JIANG. Research advances in biomarkers for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2023, 39(9): 2225-2230. doi: 10.3969/j.issn.1001-5256.2023.09.029
[2]	Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019
[3]	LI Yan, LU LunGen, CAI XiaoBo. Advances in the treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2415-2418. doi: 10.3969/j.issn.1001-5256.2020.11.004
[4]	LIAO XianHua, YE JunZhao, ZHONG BiHui. Pathogenesis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2406-2410. doi: 10.3969/j.issn.1001-5256.2020.11.002
[5]	LI XiaoYun, HUA Jing. Treatment of hepatorenal syndrome:Vasoconstriction or vasodilation?[J]. Journal of Clinical Hepatology, 2020, 36(11): 2419-2422. doi: 10.3969/j.issn.1001-5256.2020.11.005
[6]	Tan YanXin, Long FuLi, Mao DeWen, Zhang JianLing, Ma YuZhen, Yan LianJie. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2266-2271. doi: 10.3969/j.issn.1001-5256.2019.10.027
[7]	Song TingXue, Qi XingShun, Gao Fan, Guo XiaoZhong. Advances in diagnosis and treatment of hepatorenal syndrome type of acute kidney injury in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 572-576. doi: 10.3969/j.issn.1001-5256.2017.03.039
[8]	Chen Li, Mei Yong, Yang YiBin, Cao MingYan. Research advances in renal replacement therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2016, 32(3): 605-608. doi: 10.3969/j.issn.1001-5256.2016.03.046
[9]	Zhan GuoQing, Li Fang, Li RuGui, Guo Peng, Liu Xiang, Zhang WeiWei, Tan HuaBing. Efficacy of terlipressin therapy for refractory ascites in cirrhosis and type-2 hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2015, 31(8): 1287-1290. doi: 10.3969/j.issn.1001-5256.2015.08.025
[10]	Liang Chao, Sha YingYing, Zhu XiaoMing, Wang XiongDa, Zhu YuHua, Zhao ZhenYu. Early changes in hemorheological parameters and TXA2 and PGI2 levels among patients with severe acute pancreatitis[J]. Journal of Clinical Hepatology, 2014, 30(6): 549-551. doi: 10.3969/j.issn.1001-5256.2014.06.018
[11]	Zheng XiaoLi, Wang LiangZhi, He JianHua, Xiang XingChao, Zhou XiangYu. Diagnostic value of serum cystatin C and urotensin II for hepatorenal syndrome in patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(8): 627-630. doi: 10.3969/j.issn.1001-5256.2013.08.019
[12]	Xiao Qian, Zhang Yang, Tan ShanZhong. The treatment by warming the kidney and promoting diuresis with Alprostadil in liver cirrhosis complicated with hepato-renal syndrome in 29 cases[J]. Journal of Clinical Hepatology, 2012, 28(3): 189-191.
[13]	Wang JiYao. The difficulties in diagnosis and treatment of hepatorenal syndrome-raised by clinical cases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1019-1021.
[14]	Xie YongPeng, Hou Yue, Zang XiuXian, Chu Zhe. The development of treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(5): 558-561.
[15]	Zheng XiaoLi, Wang LiangZhi. Current diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(1): 107-109.
[16]	Xu XiaoYuan, Zheng YingYing. Hepatorenal syndrome-vasoconstrictor or vasodilator?[J]. Journal of Clinical Hepatology, 2011, 27(8): 801-803+817.
[17]	Fu Qiang, Tang TongYu. Advance in research of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2010, 26(5): 557-560.
[18]	Chen FuMing, Huang Qun, Ji RengBin, Li GuiXia. The significance of serum TNF-α determination in patients with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2007, 23(6): 436-438.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2100) PDF downloads(544)

Implications of elevated levels of prostaglandin I2 and thromboxane A2 in type I hepatorenal syndrome

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Implications of elevated levels of prostaglandin I2 and thromboxane A2 in type I hepatorenal syndrome

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content